Epstein Secrets

Classification: Confidential Jeffrey — we are following up with the below news regarding AAVL. The stock is trading down $19.11 to $19.7657 per the Bloomberg screenshot below. Please let us know how you would like to proceed with your position. Thank you, Vahe AAVL US $ S I 19./6S/ 819.76 /19.86K 1

ns from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The study assessed AVA-101's safety for patients with the disease, called wet age-related macular degeneration or wet AMD. Although the study wasn't designed to show statistic

EPORTS 2Q '15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA

erg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA-101 for potential treatment of wet age-related macular degeneration. AAVL down 20% post-mkt after 112k shrs traded. * AAVL instead will run added precl

EFTA00848766 Source: Bloomberg Avalanche Bio Drops 14%; Analysts Halve PTs on Wet AMD Update 2015-08-14 12:37:45.493 GMT By Cristin Flanagan (Bloomberg) -- Avalanche Biotech drops 14% in pre-mkt trading after announcing post-mkt yday plans to scrap a planned Phase 2b trial and instead initiate added

uncing post-mkt yday plans to scrap a planned Phase 2b trial and instead initiate added preclinical studies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). * "Investors need a clear path forward" before getting back in AAVL, Cowen analyst

g Avalanche Bio Drops 14%; Analysts Halve PTs on We= AMD Update 2015-08-14 12:37:45.493 GMT By Cristin Flanagan EFTA_R1_02173658 EFTA02718803 (Bloomberg) -- Avalanche=Biotech drops 14% in pre-mkt trading after announcing post-mkt yday plans =o scrap a planned Phase 2b trial and instead initiate added

uncing post-mkt yday plans =o scrap a planned Phase 2b trial and instead initiate added preclinical st=dies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). • "Investors need a clear path forward=94 before getting back in AAVL, Cowen analys

ne Therapy Trial Miss High Expectations (1) 2015-06.15 21:36:53.569 GMT (Updates with analyst's comment in fourth paragraph.) By Danielle Burger (Bloomberg) -- Avalanche Biotechnologies Inc. shares tumbled after some patients in a safety study of its gene therapy for an age-related chronic eye disease s

ns from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The study assessed AVA-101's safety for patients with the disease, called wet age-related macular degeneration or wet AMD. Although the study wasn't designed to show statistic

REPORTS 2Q'15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA

erg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA-101 for potential treatment of wet age-related macular degeneration. AAVL down 20% post-mkt after 112k shrs traded. * AAVL instead will run added precl